158. Tuberous sclerosis Clinical trials / Disease details
Clinical trials : 108 / Drugs : 67 - (DrugBank : 17) / Drug target genes : 35 - Drug target pathways : 118
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05059327 (ClinicalTrials.gov) | November 22, 2021 | 20/8/2021 | Basimglurant in Children and Adolescents With TSC | A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children and Adolescents With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex | Tuberous Sclerosis Complex | Drug: Basimglurant with crossover to Placebo;Drug: Placebo with crossover to Basimglurant | Noema Pharma AG | NULL | Not yet recruiting | 5 Years | 18 Years | All | 55 | Phase 2 | NULL |